Country: Ireland
Language: English
Source: HPRA (Health Products Regulatory Authority)
DOXORUBICIN HYDROCHLORIDE
Genepharm (Europe) Trading Ltd
L01DB; L01DB01
DOXORUBICIN HYDROCHLORIDE
2 milligram(s)/millilitre
Concentrate for solution for infusion
Product subject to prescription which may not be renewed (A)
Anthracyclines and related substances; doxorubicin
Not marketed
2009-11-13
Health Products Regulatory Authority 16 November 2018 CRN008L43 Page 1 of 11 SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Doxorubicin 2mg/ml Concentrate for Solution for Infusion 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Doxorubicin hydrochloride 1ml contains 2 mg Doxorubicin hydrochloride. Each 5ml vial contains 10 mg of Doxorubicin hydrochloride. Each 10ml vial contains 20 mg of Doxorubicin hydrochloride. Each 25ml vial contains 50 mg of Doxorubicin hydrochloride. Each 50ml vial contains 100 mg of Doxorubicin hydrochloride. Each 100ml vial contains 200 mg of Doxorubicin hydrochloride. Excipients: The product contains sodium chloride (3.54 mg sodium per 1 ml). For a full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Concentrate for solution for infusion Red concentrate for infusion. pH = 2.5 – 3.5 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Breast cancer, sarcoma, small-cell carcinoma of the lung, Hodgkin disease or non-Hodgkin lymphoma, acute leukaemia, cancer of the thyroid, bladder, ovaries, Paediatric tumours, such as neuroblastoma. Doxorubicin is frequently used in combination chemotherapy regimens with other cytotoxic drugs. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Treatment with Doxorubicin 2mg/ml Concentrate for Solution for Infusion should be started by or after consultation with a doctor with extensive experience from cytostatic treatment. The concentrate is injected via the tubing of a freely-running intravenous infusion (Sodium chloride 0.9% intravenous infusion or Dextrose 5% intravenous infusion) Health Products Regulatory Authority 16 November 2018 CRN008L43 Page 2 of 11 over 2-15 minutes. This technique minimizes the risk of thrombophlebitis or perivenous extravasation which can lead to severe cellulitis and vesication. Intravenous administration: The dosage of doxorubicin depends on dosage regimen, general status and previous treatment of the patient. Several dosage regimens exist: The recommended dose is 60-75 mg/m² body surface i.v. as a single do Read the complete document